Your browser is no longer supported. Please, upgrade your browser.
Settings
GRFS Grifols, S.A. daily Stock Chart
GRFS [NASD]
Grifols, S.A.
Index- P/E32.58 EPS (ttm)0.60 Insider Own- Shs Outstand684.14M Perf Week5.57%
Market Cap13.36B Forward P/E12.93 EPS next Y1.51 Insider Trans- Shs Float- Perf Month22.98%
Income- PEG2.88 EPS next Q0.35 Inst Own53.68% Short Float- Perf Quarter-1.46%
Sales- P/S- EPS this Y14.40% Inst Trans- Short Ratio4.15 Perf Half Y-4.96%
Book/sh3.56 P/B5.49 EPS next Y11.90% ROA- Target Price25.00 Perf Year-6.02%
Cash/sh- P/C- EPS next 5Y11.30% ROE- 52W Range13.40 - 25.73 Perf YTD-16.14%
Dividend0.44 P/FCF- EPS past 5Y2.78% ROI- 52W High-25.61% Beta-
Dividend %2.25% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low42.84% ATR0.59
Employees24162 Current Ratio- Sales Q/Q9.30% Oper. Margin- RSI (14)63.06 Volatility3.03% 2.71%
OptionableYes Debt/Eq- EPS Q/Q-81.50% Profit Margin- Rel Volume0.68 Prev Close19.53
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.48M Price19.14
Recom1.70 SMA207.13% SMA5011.80% SMA200-3.21% Volume859,092 Change-2.00%
Oct-01-20Upgrade Citigroup Sell → Neutral
Jun-09-20Upgrade HSBC Securities Reduce → Hold
Jun-09-20Downgrade Citigroup Neutral → Sell
Mar-25-20Downgrade Citigroup Buy → Neutral
Jun-27-19Upgrade JP Morgan Neutral → Overweight
Feb-08-19Downgrade Berenberg Buy → Hold
Oct-11-18Upgrade Berenberg Hold → Buy
Jun-01-18Initiated Barclays Overweight
Oct-31-17Initiated Citigroup Buy
Jun-30-17Downgrade Goldman Buy → Neutral
Apr-06-17Initiated BofA/Merrill Buy
Jan-03-17Upgrade JP Morgan Neutral → Overweight
Feb-09-16Upgrade Berenberg Hold → Buy
Jan-04-16Downgrade Morgan Stanley Equal-Weight → Underweight
Dec-02-15Downgrade HSBC Securities Buy → Hold
Nov-20-15Downgrade Berenberg Buy → Hold
Apr-28-15Downgrade Berenberg Buy → Hold
Oct-09-20 05:30AM  
Oct-07-20 12:45PM  
Oct-01-20 12:13PM  
12:13PM  
Sep-08-20 10:46AM  
02:17AM  
Sep-07-20 02:50AM  
Aug-26-20 07:00AM  
Aug-10-20 04:00PM  
Aug-05-20 06:04PM  
02:01AM  
Jul-28-20 10:41AM  
Jul-27-20 01:18PM  
Jul-23-20 08:00AM  
Jul-20-20 07:39AM  
02:55AM  
02:39AM  
02:36AM  
Jul-17-20 12:45PM  
Jul-09-20 03:57PM  
08:19AM  
Jun-30-20 11:18AM  
Jun-24-20 04:22AM  
Jun-19-20 01:12AM  
Jun-12-20 11:54AM  
Jun-11-20 08:12AM  
04:03AM  
May-26-20 09:00AM  
May-07-20 12:06PM  
09:00AM  
Apr-28-20 09:00AM  
Apr-27-20 11:40AM  
Apr-20-20 02:53PM  
09:00AM  
01:27AM  
Apr-09-20 11:40AM  
Apr-06-20 09:30AM  
Mar-31-20 10:12AM  
Mar-26-20 08:23AM  
Mar-25-20 05:25PM  
03:55PM  
Mar-21-20 12:52PM  
Mar-18-20 11:48AM  
Mar-05-20 12:00PM  
09:34AM  
Feb-27-20 11:40AM  
Feb-21-20 07:52AM  
Feb-19-20 07:21AM  
Feb-18-20 07:37AM  
Feb-13-20 09:00AM  
Feb-11-20 11:40AM  
Feb-10-20 05:00AM  
Jan-06-20 11:07PM  
Dec-12-19 09:24AM  
Dec-09-19 10:22AM  
Dec-06-19 03:42PM  
Dec-05-19 10:26AM  
Dec-02-19 09:17AM  
Nov-19-19 06:27AM  
Nov-07-19 10:00AM  
Oct-14-19 01:22AM  
Oct-11-19 11:15AM  
Sep-16-19 01:54AM  
Aug-23-19 04:08AM  
Jul-31-19 04:54AM  
Jul-16-19 02:39AM  
Jul-08-19 09:22AM  
05:06AM  
Jul-05-19 04:17PM  
08:55AM  
Jul-04-19 11:51AM  
Jul-03-19 05:00AM  
Jun-29-19 08:13PM  
Jun-27-19 04:34PM  
Jun-19-19 09:00AM  
Jun-12-19 08:15AM  
Jun-06-19 06:39AM  
May-20-19 06:43PM  
May-09-19 09:30AM  
May-08-19 12:23AM  
Apr-30-19 06:00AM  
Apr-29-19 12:00PM  
03:14AM  
Apr-18-19 09:00AM  
Apr-15-19 06:15AM  
Apr-05-19 10:55AM  
Apr-02-19 06:46AM  
Mar-31-19 12:17PM  
Mar-23-19 09:00AM  
Mar-07-19 04:03AM  
03:32AM  
Mar-01-19 09:18AM  
Feb-21-19 11:22AM  
Feb-19-19 05:54PM  
05:30PM  
Feb-07-19 12:31PM  
Feb-05-19 05:29AM  
Jan-23-19 10:20AM  
07:51AM  
07:30AM  
Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.